NASDAQ:ACHV Achieve Life Sciences Q3 2026 Earnings Results & Report $6.70 -0.08 (-1.11%) Closing price 11/9/2026 07:30 PM EasternExtended Trading$6.70 0.00 (0.00%) As of 11/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Achieve Life Sciences beat analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.11 versus the -$0.1997 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market Opens Achieve Life Sciences EPS ResultsActual EPS-$0.11Consensus EPS -$0.1997Beat/MissBeat by +$0.0897One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersAchieve Life Sciences Revenue ResultsActual RevenueN/AExpected Revenue$10.65 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Achieve Life Sciences Q3 2026 Earnings FAQ Did Achieve Life Sciences beat earnings estimates for Q3 2026? Achieve Life Sciences (NASDAQ:ACHV) reported earnings of -$0.11 per share for Q3 2026, beating the consensus estimate of -$0.1997. The report was announced on Tuesday, November 10, 2026. Achieve Life Sciences Earnings HeadlinesAchieve Life Sciences Rebrands as AchieveRx, The Quit CompanyNovember 9 at 2:03 PM | marketscreener.comMAchieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUITNovember 9 at 8:00 AM | globenewswire.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 10 at 1:00 AM | American Alternative (Ad)Achieve Life Sciences Announces Granting of New Hire Inducement AwardsNovember 2, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), InflaRx (IFRX) and Achieve Life Sciences (ACHV)October 25, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Achieve Life Sciences (ACHV), AngioDynamics (ANGO)October 23, 2026 | theglobeandmail.comSee More Achieve Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Achieve Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achieve Life Sciences and other key companies, straight to your email. Email Address About Achieve Life SciencesAchieve Life Sciences (NASDAQ:ACHV) is a clinical-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a therapy designed to help adults quit smoking and overcome nicotine addiction. Cytisinicline is an oral, plant-based small molecule that partially activates nicotinic acetylcholine receptors, with the goal of reducing nicotine cravings and withdrawal symptoms. The company has evaluated cytisinicline in clinical studies involving adults who smoke cigarettes, including trials assessing smoking cessation and cessation of electronic cigarette use. Achieve has advanced the product through late-stage development in the United States and has worked toward regulatory approval. Cytisinicline is not an approved product in the United States, and the company’s activities remain centered on clinical development and commercialization planning. Achieve Life Sciences was formed through the combination of Achieve Pharma and OncoGenex Pharmaceuticals, a transaction completed in 2017. The company is headquartered in Vancouver, British Columbia, and maintains operations in the United States. Its leadership has included John Bencich as chief executive officer and members of its medical and clinical development team focused on addiction medicine and regulatory strategy.View Achieve Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
